These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36908576)

  • 21. Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access.
    Maponga TG; Matteau Matsha R; Morin S; Scheibe A; Swan T; Andrieux-Meyer I; Spearman CW; Klein MB; Rockstroh JK
    Hepatol Med Policy; 2017; 2():8. PubMed ID: 30288321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
    Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
    Elife; 2021 Aug; 10():. PubMed ID: 34342266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment.
    Lourenço L; Kelly M; Tarasuk J; Stairs K; Bryson M; Popovic N; Aho J
    Can Commun Dis Rep; 2021 Dec; 47(12):561-570. PubMed ID: 35692566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Second Canadian Symposium on hepatitis C virus: a call to action.
    Grebely J; Bilodeau M; Feld JJ; Bruneau J; Fischer B; Raven JF; Roberts E; Choucha N; Myers RP; Sagan SM; Wilson JA; Bialystok F; Tyrrell DL; Houghton M; Krajden M;
    Can J Gastroenterol; 2013 Nov; 27(11):627-32. PubMed ID: 24199209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.
    Gowda C; Lo Re V
    Curr Hepatol Rep; 2018 Jun; 17(2):111-120. PubMed ID: 30294518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy.
    Lazarus JV; Roel E; Elsharkawy AM
    Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Securing wider EU commitment to the elimination of hepatitis C virus.
    Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
    Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis.
    Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B
    J Viral Hepat; 2021 Oct; 28(10):1340-1354. PubMed ID: 34310812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?
    Høj SB; Minoyan N; Artenie AA; Grebely J; Bruneau J
    Can Liver J; 2018; 1(2):4-13. PubMed ID: 35990720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal.
    Sarrazin C; Boesecke C; Golsabahi-Broclawski S; Moog G; Negro F; Silaidos C; Patel P; Lohmann K; Spinner CD; Walcher S; Wedemeyer H; Wörns MA
    Health Sci Rep; 2021 Jun; 4(2):e290. PubMed ID: 34136654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis.
    Gamkrelidze I; Pawlotsky JM; Lazarus JV; Feld JJ; Zeuzem S; Bao Y; Gabriela Pires Dos Santos A; Sanchez Gonzalez Y; Razavi H
    Liver Int; 2021 Mar; 41(3):456-463. PubMed ID: 33389788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral hepatitis C pandemic: Challenges and threats to its elimination.
    Krekulova L; Honzák R; Riley LW
    J Viral Hepat; 2021 May; 28(5):694-698. PubMed ID: 33550694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
    Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D;
    BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
    Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
    Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contextualizing Canada's hepatitis C virus epidemic.
    Krajden M; Cook D; Janjua NZ
    Can Liver J; 2018; 1(4):218-230. PubMed ID: 35992621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C elimination: a Public Health Perspective.
    Dhiman RK; Grover GS; Premkumar M
    Curr Treat Options Gastroenterol; 2019 Sep; 17(3):367-377. PubMed ID: 31321673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy.
    Bird K; Socías ME; Ti L
    Int J Drug Policy; 2018 Sep; 59():1-2. PubMed ID: 29960218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.